scholarly journals Cost-Minimization Analysis of Pembrolizumab Monotherapy Versus Nivolumab in Combination with Ipilimumab as First-Line Treatment for Metastatic PD-L1-Positive Non-small Cell Lung Cancer: A US Payer Perspective

2021 ◽  
Author(s):  
Nan Qiao ◽  
Ralph Insinga ◽  
Thomas Burke ◽  
Gilberto Lopes
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Cost Minimization ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
First Line ◽  
Payer Perspective ◽  
First Line Treatment

Real-world outcomes for patients with metastatic non-small cell lung cancer according to first-line treatment

2021 ◽  
Vol 69 ◽  
pp. S36
Author(s):  
Y. Belaroussi ◽  
S. Cousin ◽  
M. Carton ◽  
M. Lebitasy ◽  
L. Laborde ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Real World ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
First Line ◽  
First Line Treatment

First-line treatment in advanced non-small-cell lung cancer: the emerging role of the histologic subtype

2009 ◽  
Vol 9 (4) ◽  
pp. 425-435 ◽  
Author(s):  
Marcello Tiseo ◽  
Marco Bartolotti ◽  
Francesco Gelsomino ◽  
Andrea Ardizzoni
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
First Line ◽  
Histologic Subtype ◽  
First Line Treatment

Pemetrexed approved for the first-line treatment of non-small-cell lung cancer: summary of the NICE appraisal

2009 ◽  
Vol 10 (11) ◽  
pp. 1031-1032 ◽  
Author(s):  
Panagiota Vrouchou ◽  
Prashanth Kandaswamy ◽  
Elisabeth George ◽  
David Barnett
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
First Line ◽  
First Line Treatment
Sign in / Sign up

Export Citation Format

Share Document